TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15900006

Group type: EXPERIMENTAL
Intervention: Meta-analyses
Number of subjects: 2646

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials
Number of subjects: 2646

Group type: COMPARATOR
Intervention: Epidemiological studies, nonsystematic review articles, decision and cost-effectiveness analyses
Number of subjects: 2646

Group type: COMPARATOR
Intervention: Case reports
Number of subjects: 2646

Group type: EXPERIMENTAL
Intervention: Meta-analyses (limited to studies addressing treatment effects)
Number of subjects: 2646
Study: 12847067

Group type: EXPERIMENTAL
Intervention: DASH diet (27% total fat, 6% saturated fat) for 12 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control diet (37% total fat, 16% saturated fat) for 12 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: DASH diet (27% total fat, 6% saturated fat) for 12 weeks in participants with low baseline CRP
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: DASH diet (27% total fat, 6% saturated fat) for 12 weeks in participants with high baseline CRP
Number of subjects: 100
Study: 10029478

Group type: EXPERIMENTAL
Intervention: Subperiosteal nasal floor augmentation with Surgicel
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no subperiosteal pocket and no Surgicel)
Number of subjects: 64
Study: 8659717

Group type: COMPARATOR
Intervention: Morphine 1 mg/mL
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Morphine 1 mg/mL plus lidocaine 10 mg/mL
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Morphine 1 mg/mL plus lidocaine 20 mg/mL
Number of subjects: 195
Study: 1794158

Group type: EXPERIMENTAL
Intervention: Clomipramine 150 mg/day administered at noon
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clomipramine 150 mg/day administered at morning or before bedtime
Number of subjects: 40

Group type: COMPARATOR
Intervention: Clomipramine administered three times a day by traditional, equally divided doses
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clomipramine 150 mg/day
Number of subjects: 40
Study: 6363078

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg (N10)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg (N20)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30906769

Group type: EXPERIMENTAL
Intervention: CASP8 SNP rs6704688
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: CASP7 haplotype GC
Number of subjects: 540
Study: 28368938

Group type: EXPERIMENTAL
Intervention: Tapered-shaped cuff (Group T)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Cylindrical cuff (Group C)
Number of subjects: 191
Study: 26922537

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 15mg/d
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40mg/d
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40mg/d + Ezetimibe 10mg/d
Number of subjects: 30
Study: 23668824

Group type: EXPERIMENTAL
Intervention: Triclosan-containing toothpaste (3000 μg/mL TCS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo toothpaste
Number of subjects: 40
Study: 22196407

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tizanidine
Number of subjects: 40
Study: 19874111

Group type: EXPERIMENTAL
Intervention: Lawson vision intervention
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Phono-Graphix intervention
Number of subjects: 88

Group type: COMPARATOR
Intervention: Parental Literacy Support (Control)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Lawson and Phono-Graphix interventions
Number of subjects: 88
Study: 17406798

Group type: EXPERIMENTAL
Intervention: Paclitaxel-containing radiochemotherapy (paclitaxel 25-35 mg/m² twice weekly)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Radiation treatment administered to a total dose of 45-60 Gy
Number of subjects: 42
Study: 14695786

Group type: EXPERIMENTAL
Intervention: PEG‐IFN (0.5 microg/body weight/week) and ribavirin (1,000 mg-1,200 mg/daily) for 48 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: PEG‐IFN plus ribavirin
Number of subjects: 15
Study: 11333004

Group type: EXPERIMENTAL
Intervention: Substance abuse in the family of origin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dissociation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Offspring codependency
Number of subjects: 0
Study: 9208361

Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg) administered alone
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg) administered after ranitidine treatment
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg) with cola beverage
Number of subjects: 33

Group type: COMPARATOR
Intervention: Ranitidine treatment (gastric pH at least 6.0)
Number of subjects: 33
Study: 8119049

Group type: EXPERIMENTAL
Intervention: Theophylline target concentration of 10 mg/L
Number of subjects: 174

Group type: COMPARATOR
Intervention: Theophylline target concentration of 20 mg/L
Number of subjects: 174
Study: 3301053

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quinidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29310645

Group type: EXPERIMENTAL
Intervention: liraglutide
Number of subjects: 60

Group type: COMPARATOR
Intervention: metformin
Number of subjects: 60
Study: 27070727

Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention (BMI, n = 145)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Assessment Only (AO, n = 124)
Number of subjects: 269
Study: 24846807

Group type: EXPERIMENTAL
Intervention: BMI quartile 1 (<24.5 kg/m²)
Number of subjects: 3579

Group type: EXPERIMENTAL
Intervention: BMI quartile 2 (24.5 to <27.1 kg/m²)
Number of subjects: 3579

Group type: EXPERIMENTAL
Intervention: BMI quartile 3 (27.1 to 30.1 kg/m²)
Number of subjects: 3579

Group type: EXPERIMENTAL
Intervention: BMI quartile 4 (>30.1 kg/m²)
Number of subjects: 3579
Study: 23237436

Group type: EXPERIMENTAL
Intervention: ω-3 PUFA treatment (1 g/day for 6 months)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (standard therapy only)
Number of subjects: 140
Study: 20354834

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1,200 mg d(‐1) for 8 days prior to exercise trial and 600 mg on the day of exercise trial
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 15
Study: 18622600

Group type: EXPERIMENTAL
Intervention: Brain natriuretic peptide (BNP) infusion at 16.2 pmol/min for 30 min
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atrial natriuretic peptide (ANP) infusion at 16.2 pmol/min for 30 min
Number of subjects: 0
Study: 16317123

Group type: EXPERIMENTAL
Intervention: High-ALA diet (7 En% LA, 1.1 En% ALA)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Low-LA diet (3 En% LA, 0.4 En% ALA)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control diet (7% of energy as LA and 0.4 En% as ALA)
Number of subjects: 54
Study: 12598065

Group type: EXPERIMENTAL
Intervention: Ximelagatran (15, 30 or 60 mg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: r-hirudin (intravenous)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Enoxaparin (subcutaneous)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Ximelagatran (60 mg)
Number of subjects: 120
Study: 12752357

Group type: EXPERIMENTAL
Intervention: Induction interferon plus ribavirin (II + R)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Induction interferon plus placebo (II + P)
Number of subjects: 218
Study: 9708720

Group type: EXPERIMENTAL
Intervention: Atropine sulfate 0.050% nasal spray, 50 microg, 4 times daily for 2 weeks
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Atropine sulfate 0.075% nasal spray, 75 microg, 4 times daily for 2 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 45
Study: 8570772

Group type: EXPERIMENTAL
Intervention: Pindolol pretreatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: mCPP
Number of subjects: 8
Study: 1982747

Group type: EXPERIMENTAL
Intervention: 0.25% apraclonidine hydrochloride
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.50% apraclonidine hydrochloride
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 359398

Group type: EXPERIMENTAL
Intervention: Atenolol (ICI 66082) 100 mg daily for 30 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo treatment for 30 days
Number of subjects: 40
Study: 31094935

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 28510350

Group type: EXPERIMENTAL
Intervention: Nebulised hypertonic saline (administered 38.7%–74.7% of the time in Ward A and Ward B)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Nebulised hypertonic saline (administered infrequently at 6.7% in Ward C)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Adrenaline (used in conjunction with nebulised hypertonic saline)
Number of subjects: 286
Study: 23895463

Group type: EXPERIMENTAL
Intervention: Antiseptic silver alloy-coated silicone urinary catheters
Number of subjects: 742

Group type: COMPARATOR
Intervention: Standard urinary catheters
Number of subjects: 742
Study: 21768453

Group type: EXPERIMENTAL
Intervention: Epirubicin followed by docetaxel (EPI-DOC)
Number of subjects: 803

Group type: COMPARATOR
Intervention: Epirubicin alone (EPI × 6)
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: EPI-DOC
Number of subjects: 803
Study: 19295302

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Retrospective studies
Number of subjects: 0
Study: 16881427

Group type: EXPERIMENTAL
Intervention: Prechop MPF
Number of subjects: 100

Group type: COMPARATOR
Intervention: Phacoemulsification
Number of subjects: 100
Study: 15504138

Group type: EXPERIMENTAL
Intervention: Benidipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 0
Study: 11342919

Group type: EXPERIMENTAL
Intervention: PSA screening
Number of subjects: 56

Group type: COMPARATOR
Intervention: Nonscreened controls
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Screening detected tumors
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Latent tumors
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Clinically detected organ confined tumors
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Randomized control tumors
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Metastatic tumors
Number of subjects: 56
Study: 9001307

Group type: EXPERIMENTAL
Intervention: Inhaled indomethacin (3 mg/m2 body surface area)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 9
Study: 8515850

Group type: EXPERIMENTAL
Intervention: Ketorolac (30 mg i.m. every 6 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Buprenorphine (0.3 mg i.m. every 12 hours)
Number of subjects: 0
Study: 2887613

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg h.s.
Number of subjects: 1031

Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg b.i.d.
Number of subjects: 1031

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg b.i.d.
Number of subjects: 1031

Group type: COMPARATOR
Intervention: Ranitidine 150 mg b.i.d.
Number of subjects: 1031
Study: 30982861

Group type: EXPERIMENTAL
Intervention: Glucoraphanin-rich broccoli soup (300 mL weekly)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (standard broccoli soup, 300 mL weekly)
Number of subjects: 49
Study: 28453446

Group type: EXPERIMENTAL
Intervention: Neural mobilization with manual cervical traction (NMCT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Manual cervical traction (MCT)
Number of subjects: 30
Study: 26486855

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (Xeomin, Merz, Germany; 50 U/1 mL at each fat pad)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (0.9% normal saline, 1 mL at each fat pad)
Number of subjects: 60
Study: 23717976

Group type: EXPERIMENTAL
Intervention: Compound Xiatianwu tablets (2 tablets each time, 3 times/day for 3 months)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Leflunomide, sulfasalazine, and celecoxib (control group)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Xiatianwu group (not specified dosage or duration)
Number of subjects: 180
Study: 22107692

Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation (RCA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 20
Study: 19035979

Group type: EXPERIMENTAL
Intervention: Alendronate (5 mg/day)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Alfacalcidol (1 microg/day)
Number of subjects: 39
Study: 18186963

Group type: EXPERIMENTAL
Intervention: Pemetrexed
Number of subjects: 92

Group type: COMPARATOR
Intervention: RAD001
Number of subjects: 92
Study: 15031272

Group type: EXPERIMENTAL
Intervention: Life-skills approach intervention consisting of 21 sessions over 4 months.
Number of subjects: 1024

Group type: COMPARATOR
Intervention: Control group with no specific intervention.
Number of subjects: 1024
Study: 11394462

Group type: EXPERIMENTAL
Intervention: Fixed-interval observational protocols
Number of subjects: 5

Group type: COMPARATOR
Intervention: Electronic postural assessment system with video analysis
Number of subjects: 5
Study: 9713670

Group type: EXPERIMENTAL
Intervention: Special Intervention (SI) - diet intervention consisting of interactive mailings, computer‐generated phone calls, and classes for 6 months.
Number of subjects: 165

Group type: COMPARATOR
Intervention: Usual Care (UC) - control group receiving standard care without the diet intervention.
Number of subjects: 165

Group type: COMPARATOR
Intervention: Comparison of SI vs UC
Number of subjects: 165
Study: 8028316

Group type: EXPERIMENTAL
Intervention: Group 1 children listened to a variety of correctly and incorrectly produced versions of the word 'shoe'
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Group 2 children listened to the words 'shoe' and 'moo'
Number of subjects: 27

Group type: COMPARATOR
Intervention: Group 3 children listened to the words 'cat' and 'Pete'
Number of subjects: 27
Study: 2659299

Group type: EXPERIMENTAL
Intervention: Total Contact Casting (TCC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional Dressing Treatment (TDT)
Number of subjects: 40
Study: 235714

Group type: EXPERIMENTAL
Intervention: Hydrallazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazoxide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minoxidil
Number of subjects: 0
Study: 31870438

Group type: EXPERIMENTAL
Intervention: AMA (Ambulatory Medical Assistance)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: AMA and Control group
Number of subjects: 100
Study: 28477375

Group type: EXPERIMENTAL
Intervention: l-tyrosine (150 mg kg-1)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 26134076

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (Zn sulfate 70 mg daily for 16 weeks)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (identical capsules containing wheat starch with no added Zn)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Control group with Zinc supplementation (Zn sulfate 70 mg daily for 16 weeks)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group with Placebo (identical capsules containing wheat starch with no added Zn)
Number of subjects: 25
Study: 23343453

Group type: EXPERIMENTAL
Intervention: Clozapine (TR-C group)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics other than clozapine (NTR group)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: NTR group
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: TR-C group
Number of subjects: 64
Study: 21219223

Group type: EXPERIMENTAL
Intervention: Bupivacaine infusion
Number of subjects: 65

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 65
Study: 18583448

Group type: EXPERIMENTAL
Intervention: Home telecare for management of acute exacerbations of COPD
Number of subjects: 20
Study: 16920550

Group type: EXPERIMENTAL
Intervention: Acetaminophen-codeine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12900093

Group type: EXPERIMENTAL
Intervention: Detailed decision aid plus worksheet
Number of subjects: 34

Group type: COMPARATOR
Intervention: Pamphlet
Number of subjects: 34
Study: 10717524

Group type: EXPERIMENTAL
Intervention: Breast conserving operation with postoperative radiotherapy
Number of subjects: 331

Group type: COMPARATOR
Intervention: Breast conserving operation without postoperative radiotherapy
Number of subjects: 331
Study: 8940320

Group type: EXPERIMENTAL
Intervention: Counseling and support intervention (6 sessions of individual and family counseling within 4 months and support groups)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Counseling and support intervention
Number of subjects: 206
Study: 1587959

Group type: EXPERIMENTAL
Intervention: bezafibrate (400 mg daily)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: simvastatin (20 mg daily)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: combined bezafibrate-simvastatin
Number of subjects: 13

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 13
Study: 3896372

Group type: EXPERIMENTAL
Intervention: Single layer interrupted extramucosal sutures
Number of subjects: 118

Group type: COMPARATOR
Intervention: Circular staple gun
Number of subjects: 118
Study: 31444196

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29505603

Group type: EXPERIMENTAL
Intervention: Fear Avoidance Model (FAM) variables including BDI and FABQ-work subscale
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Baseline FAM measures
Number of subjects: 60
Study: 27716422

Group type: EXPERIMENTAL
Intervention: YXBCM01 granule 5.5 g twice daily for 12 weeks
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo granules 5.5 g twice daily for 12 weeks
Number of subjects: 600
Study: 24518614

Group type: EXPERIMENTAL
Intervention: CADEES items related to insurance coverage of eye examination costs
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: CADEES items related to general barriers to obtaining eye examinations
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: CADEES items related to prioritizing eye examinations
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: CADEES items related to awareness of diabetic eye disease visibility through examination
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Lower hemoglobin A1c levels
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Having insurance
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Longer duration of diabetes
Number of subjects: 316
Study: 22898340

Group type: EXPERIMENTAL
Intervention: Cardiac shock wave therapy (CSWT) performed 3 times within 3 months (Group A, n = 20)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Cardiac shock wave therapy (CSWT) performed 3 sessions/week for 1 month (Group B, n = 21)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (n = 14) received only medical therapy
Number of subjects: 55
Study: 20594339

Group type: EXPERIMENTAL
Intervention: Test for Substitution Patterns (TSP)
Number of subjects: 53
Study: 18060588

Group type: EXPERIMENTAL
Intervention: 750 mL orange juice (containing 0.545 g PB)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: PB supplement (0.545 g PB dissolved in 750 mL apple juice)
Number of subjects: 8

Group type: COMPARATOR
Intervention: 750 mL apple juice (control)
Number of subjects: 8
Study: 14984384

Group type: EXPERIMENTAL
Intervention: Buffered acetylsalicylic acid plus ascorbic acid
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid plus paracetamol plus caffeine
Number of subjects: 17
Study: 11334921

Group type: EXPERIMENTAL
Intervention: Tamoxifen citrate (TMX)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC)
Number of subjects: 86
Study: 9656904

Group type: EXPERIMENTAL
Intervention: Tongue positioned against the anterior palate
Number of subjects: 33

Group type: COMPARATOR
Intervention: Tongue on the floor of the mouth
Number of subjects: 33
Study: 8184209

Group type: EXPERIMENTAL
Intervention: Visual model plus verbal rehearsal
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Visual model, verbal rehearsal plus cues
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Visual model plus cues
Number of subjects: 80

Group type: COMPARATOR
Intervention: Visual model only
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Visual model plus cues (adults)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Visual model plus verbal rehearsal (children)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Visual model, verbal rehearsal plus cues (children)
Number of subjects: 80
Study: 3237227

Group type: EXPERIMENTAL
Intervention: 20 mg/kg phenobarbital
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 5 mg/kg phenobarbital
Number of subjects: 20
Study: 30450925

Group type: EXPERIMENTAL
Intervention: β‐blocker uptitration
Number of subjects: 457

Group type: COMPARATOR
Intervention: Control group (higher NPs levels)
Number of subjects: 457
Study: 26900091

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy with cetuximab (Arm B)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy without cetuximab (Arm A)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both arms (A and B)
Number of subjects: 102
Study: 25605809

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline (before exercise)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-exercise (after 12 weeks of aerobic exercise)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 0
Study: 23875668

Group type: EXPERIMENTAL
Intervention: Self-HPV using a standard wet transport medium (S-WET)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Self-HPV using a dry vaginal swab (S-DRY)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Physician-sampling with Hybrid Capture HPV DNA test
Number of subjects: 120

Group type: COMPARATOR
Intervention: Comparison of S-WET and S-DRY
Number of subjects: 120

Group type: COMPARATOR
Intervention: Comparison of type-specific HPV agreement
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Self-HPV tests
Number of subjects: 120